Esther Bastiaannet

Esther Bastiaannet

Auto-generated profile, based on publicly available information

Esther Bastiaannet

Cancer Epidemiology, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, CH-8001 Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2016 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MHMiriam L. Hoven-Gondrie
Miriam L. Hoven-Gondrie
EBEsther Bastiaannet
Esther Bastiaannet
VHVincent K.Y. Ho
Vincent K.Y. Ho
BLBarbara L. Van Leeuwen
Barbara L. Van Leeuwen
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
ASAlbert J. H. Suurmeijer
Albert J. H. Suurmeijer
Nearly half of soft-tissue sarcoma (STS) patients are over the age of 65, and the behavior of cancer in these elderly patients is poorly understood. The ai

11 June 2018 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
DHDaniëlle D. Huijts
Daniëlle D. Huijts
JGJulia T. van Groningen
Julia T. van Groningen
OGOnno R. Guicherit
Onno R. Guicherit
JDJan Willem T. Dekker
Jan Willem T. Dekker
LBLeti van Bodegom-Vos
Leti van Bodegom-Vos
PMPerla J. Marang-Van de Mheen
Perla J. Marang-Van de Mheen
Background: It is unclear whether emergency weekend colon and rectal cancer surgery are associated with worse outcomes (ie, weekend effect) because previous studies mostly used administrative data, which may insufficiently adjust for case-mix. Materials and Methods: Prospectively collected data from the 2012–2015 Dutch ColoRectal Audit (n=5,224) was used to examine differences in 30-day mortality and severe complication and failure-to-rescue rates for emergency weekend (Saturday and Sunday) versus Monday surgery, stratified for colon and rectal cancer. Analyses were adjusted for age, sex, body mass index, Charlson comorbidity index, American Society of Anesthesiologists classification score, tumor stage, presence of metastasis, preoperative complication, additional resection for metastasis or locally advanced tumor, location primary colon tumor, type of rectal surgery (lower anterior resection or abdominal perineal resection), and type of neoadjuvant therapy (short-course radiotherapy or chemoradiotherapy). Results: A total of 5,052 patients undergoing colon cancer surgery and 172 undergoing rectal cancer surgery were included. Patients undergoing colon or rectal cancer surgery during weekends had significantly more preoperative tumor complications compared with those undergoing surgery on a weekday. Additionally, differences in year of surgery and location of primary tumor were found for colon cancer surgery. Emergency colon cancer surgery during the weekend was associated with increased 30-day mortality (odds ratio [OR], 1.66; 95% CI, 1.10–2.50) and severe complications (OR, 1.29; 95% CI, 1.03–1.63) compared with surgery on Monday. Estimates for emergency weekend rectal cancer surgery were similar but not statistically significant, likely explained by small numbers. Conclusions: Weekend emergency colon cancer surgery was associated with higher mortality and severe complication rates. More research is needed to understand which factors explain and contribute to these differences.

26 October 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SOSarah Ouahoud
Sarah Ouahoud
RJRutger J. Jacobs
Rutger J. Jacobs
LKLiudmila L. Kodach
Liudmila L. Kodach
PVPhilip W. Voorneveld
Philip W. Voorneveld
Lukas HawinkelsLukas Hawinkels
Lukas Hawinkels
JHJames C. H. Hardwick
James C. H. Hardwick

26 August 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
ABAnna de Boer
Anna de Boer
EBEsther Bastiaannet
Esther Bastiaannet
NGNienke de Glas
Nienke de Glas
PMPerla J. Marang-Van de Mheen
Perla J. Marang-Van de Mheen
ODOlaf M. Dekkers
Olaf M. Dekkers
GLGerrit Jan Liefers
Gerrit Jan Liefers
In the Netherlands, radiotherapy after breast-conserving surgery (BCS) is omitted in up to 30% of patients aged ≥ 75 years. Although omission of radiotherapy is considered an option for older women treated with endocrine treatment, the majority of these patients do not receive systemic treatment following Dutch treatment guidelines. Therefore, the aim of this study was to evaluate the effect of omission of radiotherapy on locoregional recurrence risk in this patient population.

27 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.

3 February 2022 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Open access
PDF file
EREva Rademaker
Eva Rademaker
EBEsther Bastiaannet
Esther Bastiaannet
JOJan Oosting
Jan Oosting
NDNeeltje G. Dekker-Ensink
Neeltje G. Dekker-Ensink
Peter KuppenPeter Kuppen
Peter Kuppen
GLGerrit J. Liefers
Gerrit J. Liefers
Purpose: Integrin subunit β4 (β4) has been proposed to play an important role in colon cancer progression through its involvement in hemidesmosome disassembly processes and tumor cell migration. However, the association between β4 expression and clinicopathological outcomes in colon cancer remains unclear. Methods: Expression of β4 was assessed by immunohistochemistry in a large cohort of 651 colon cancer patients, the largest colon cancer cohort so far. Chi-squared tests were used to study the association between β4 expression and clinicopathological features. Overall and disease-free survival were assessed by Cox proportional hazard models. Results: Loss of β4 expression was associated with local tumor invasion. Only 17.9% of the pT1 tumors displayed weak β4 expression level versus 28.1% of pT4 tumors, and 25.0% of the pT1 tumors had a high expression level versus 8.6% of the pT4 tumors (p = 0.012). No association between β4 expression and overall (p = 0.845) or disease-free survival (p = 0.767) was encountered, which disputes the role of β4 as a biomarker of malignant behavior in colon cancer. Conclusion: Contradictory reports have suggested opposite roles for β4 expression in (colon) cancer progression. In the present large cohort of colon cancer patients, we found that β4 expression was not associated with worse clinical prognosis, but decreased with advanced pathological tumor stage. Future studies should establish whether loss of β4 expression promotes invasive characteristics of colon cancer cells.